Biontech Se Sponsored Adr Stock News

BioNTech (NASDAQ:BNTX) and Cardiff Oncology (NASDAQ:CRDF) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings. Profitability This table compares BioNTech and Cardiff Oncologys net margins, return on equity and return on assets. []

Some are more optimistic than others.

Professor Saul Faust, who led the new study, said six different vaccines proved safe and effective as booster shots for people who had received two doses of AstraZeneca or Pfizer/BioNTech.

The European Union-wide rollout of Pfizer Inc (NYSE: PFE ) / BioNTech SE''s (NASDAQ: BNTX ) COVID-19 vaccine for five- to 11-year-old children will begin December 13 , one week earlier than previously planned, Germany''s health ministry said. "Given the current pandemic situation, this is good news for parents and children. Many are awaiting this eagerly," acting health minister Jens Spahn Full story available on Benzinga.com

Hotel stocks are up across the board after President Joe Biden reiterated his message that the U.S. won't face another lockdown. The post Hotel Stocks: Why MAR, H, HLT, WH, CHH and IHG Are Booking Gai

Özlem Türeci, BioNTech''s chief medical officer, was among the four winners in the sixth edition of the Women of Europe Awards held on Wednesday (1 December) by the European Movement International and the European Women''s Lobby (EWL).

The British government has agreed on deals to buy 114 million more Pfizer Inc (NYSE: PFE ) / BioNTech SE (NASDAQ: BNTX ) and Moderna Inc (NASDAQ: MRNA ) COVID-19 vaccine shots. The new contracts with Pfizer/BioNTech and Moderna were accelerated in light of the emergence of the new Omicron variant. These future supply deals include access to modified vaccines, if needed, to combat Omicron and future Variants of Concern. The deal involves an additional 60 million Moderna shots and 54 million Pfizer/BioNTech doses for next year and 2023. "These new deals Full story available on Benzinga.com

The British government has agreed on deals to buy 114 million more Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA) COVID-19 vaccine shots. The new contracts

TransitoRIP: "In Just A Few Days, The Market Was Treated With Two Big Shocks" By Michael Every of Rabobank TransitoRIP In a matter of just a few days, the market has been treated with two big shocks . Last Friday, it was the omicron scare that got markets re-pricing the risks of more restrictions and hence a slowdown for the global economy. But yesterday it was Fed Chair Powell, who added fuel to the fire. In a testimony before the Senate Banking Committee he pledged to bury the term transitory and instead recommends Fed policy makers to consider explaining more clearly what the Fed thinks/means when it is talking about inflation. Or was Powell running out of dollar bills to put in the Atlanta Feds swear jar ? We wonder if Powell now still owes Bostic a dollar for using the word while retiring it. More importantly , a lot of folks will now surely be looking forward to know what the Fed really thinks ! For example, did Powell mean to say that the effects of the temporary price rises will remain and not fade after a while?

Dr. Anthony Fauci, National Institute of Allergy and Infectious Diseases, speaks from the White House on the omicron variant, which was discovered in a patient in California.

Futures Surge After Powell-Driven Rout Proves To Be "Transitory" Heading into yesterday''s painful close to one of the ugliest months since March 2020, which saw a huge forced liquidation rebalance with more than $8 billion in Market on Close orders, we said that while we are seeing "forced selling dump into the close today" this would be followed by "forced Dec 1 buying frontrunning after the close." Forced selling dump into the close today. Forced Dec 1 buying frontrunning after the close zerohedge (@zerohedge) November 30, 2021 And just as expected, despite yesterday''s dramatic hawkish pivot by Powell, who said it was time to retire the word transitory in describing the inflation outlook (the same word the Fed used hundreds of times earlier in 2021 sparking relentless mockery from this website for being clueless as usual) while also saying the U.S. central bank would consider bringing forward plans for tapering its bond buying program at its next meeting in two weeks, the frontrunning of new monthly inflows is in full force with S&P futures rising over 1.2%, Nasdaq futures up 1.3%, and Dow futures up 0.9%, recovering almost all of Tuesdays decline.

The European Union-wide rollout of Pfizer and BioNTechs COVID-19 vaccine version for five- to 11-year-old children will begin Dec 13, one week earlier than previously planned, Germanys health ministry said on Wednesday. Germany is due to receive 2.4 million doses for use as a two-dose regimen, the ministry said, adding

WASHINGTON/TOKYO: Air travellers to the United States will face tougher COVID-19 testing rules, while more countries tightened their borders amid uncertainty around the virulence of the Omicron variant and its ability to evade vaccine protection. Japan and Hong Kong said they would expand travel curbs, Malaysia temporarily banned travellers from countries deemed at risk, while Australia braced for more cases of the coronavirus variant after at least two people visited several locations in its biggest city while likely infectious. In an attempt to stave off hasty border curbs, the World Health Organization (WHO) urged countries to apply "an evidence-informed and risk-based approach" to travel measures, saying "blanket travel bans will not prevent the international spread, and they place a heavy burden on lives and livelihoods". Investors remained on edge on Wednesday, even as financial markets came off lows plumbed a day earlier following remarks by the CEO of Moderna that raised questions about the efficacy of COVID-19 vaccines against Omicron.

The European drug regulator announced on Tuesday that it would approve vaccines adapted to Covid''s new version, Omicron, within three to four months if necessary, but existing drugs would continue to provide protection, Reuters reported. Speaking to the European Parliament, European Medicines Agency (EMA) Executive Director Emery Cook said it was not known whether drug manufacturers would have to change their vaccines to protect against Omicron, but the EMA was preparing for that possibility. "If there was a need to change existing vaccines, we could be able to approve them within three to four months," she said. "Companies that adapt their wording to include the new sequence () will then have to show that the production system works, then they will have to do some clinical trials to find that it actually works in practice. The EMA clarified in a separate statement that the review will begin when drug manufacturers decide they need to change the vaccine and start working on it. " We expect to receive smaller packages (data) that will reduce the evaluation time," said the EMA, based on the guidelines in force since February for each update of a variant-specific vaccine.

Pfizer CEO and Chairman Albert Bourla on Tuesday announced that the company and its partner BioNTech have submitted a request to the U.S. Food and Drug Administration (FDA) seeking to expand authorization for its COVID-19 booster shot for use in 16- and 17-year-olds. It comes after U.S. regulators last week expanded the eligibility for a []